These results also provide a broad insight into how cancer cells with RTK-activating mutations that drive inhibition of GSK3 may promote escape from anti-tumor immunity by preventing PD-L1 degradation and place RTK inhibitors that result in activation of GSK3 as putative enhancers of the PD-1/PD-L1 immune checkpoint blockade immunotherapies. The gene discussed is CD274; the disease is neoplasm.